NUMINUS WELLNESS INC - NUMIF STOCK NEWS

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) provided an update regarding its previously announced management cease trade order (MCTO). The order, granted by the British Columbia Securities Commission on December 2, 2024, restricts the CEO and CFO from trading company securities until the Annual Filings are completed. The delay affects the company's audited annual financial statements, MD&A, and annual information form for the year ended August 31, 2024.

During this period, Numinus will suspend share buy-back activities and won't issue or acquire securities from insiders or employees. The company expects to complete the Annual Filings by January 28, 2025. Shareholder trading remains unaffected, and the company will provide bi-weekly updates through news releases on SEDAR+.

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) has requested a temporary Management Cease Trade Order (MCTO) from the British Columbia Securities Commission due to delays in filing its audited annual financial statements for the year ended August 31, 2024. The company expects to miss the November 29, 2024 deadline but anticipates completing the Annual Filings by year-end. Numinus will issue bi-weekly status reports during the delay period and has implemented an insider trading blackout. The company confirms it is not under any insolvency proceedings and all material information has been disclosed.

Numinus Wellness has announced a strategic sale of its five Utah wellness clinics to Stella for US$3.53 million, alongside a unique data partnership agreement. The deal includes US$2.08 million paid at closing, US$750,000 in monthly installments throughout 2025, and up to US$0.7 million in deferred compensation.

The partnership grants Numinus access to operational data from Stella's network of 12 mental health clinics, enabling the development of advanced clinic management solutions. This strategic move allows Numinus to focus on developing technology-driven solutions for mental health care providers, leveraging their experience of serving 50,000 unique individuals and processing 250,000 insurance-reimbursed claims.

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) comments on the FDA's decision to not approve Lykos Therapeutics' new drug application for MDMA-assisted therapy for PTSD. The FDA has requested an additional Phase 3 study to further examine safety and efficacy. Despite this setback, Numinus remains committed to advancing psychedelic therapies and continues to execute its plan for profitability with existing operations.

Numinus clinics have delivered over 43,600 Spravato® and ketamine treatments to patients. The company's Cedar Clinical Research has conducted studies involving four psychedelic medicines with over 50 subjects in the past 2.5 years. Numinus emphasizes its ongoing clinical trials work and commitment to research partnerships as more compounds advance through late-stage trials.

Additionally, Numinus has terminated its previously announced letter of intent to acquire MedBright AI Investments Inc.

Numinus Wellness released its Q3 Fiscal 2024 results, reporting a revenue of $4.3 million, a 1.9% decline from Q2 2024. The gross profit stood at $1.0 million, down 9.8% sequentially. The company ended the quarter with a cash position of $3.7 million.

Key operational updates include a transition out of Canadian clinical operations and an increase in enrolment to over 1,650 learners in its training programs. The company managed 15 clinical trials and facilitated 15,750 client appointments in the U.S., a 3.2% increase year-over-year.

Notable subsequent events include a letter of intent to acquire MedBright AI Investments, which will result in the issuance of approximately 204,729,372 Numinus shares. The company plans to rebrand as Numinus Intelligence post-acquisition.

Gross margin declined to 22% from 24% quarter-over-quarter, while operating expenditures were reduced by $1.2 million to $6.1 million. Clinical research revenues increased by 10.7%, and practitioner training revenues surged by 114%.

Numinus Wellness will release its Q3 fiscal 2024 financial results on July 11, 2024, after market close. The company will host a conference call and webcast at 5:30 p.m. Eastern Time to review its performance and recent initiatives. A Q&A session will follow the prepared remarks, allowing qualified equity analysts to submit questions. Investors can submit questions via email to invest@numinus.com. The webcast will be archived on the company's Investor Relations page.

Dial-in information for the live call: 1 (888) 330-3632 (North America) or 1 (646) 960-0837 (International). Conference passcode: 3547386.

Numinus Wellness, a mental healthcare company known for its innovative behavioral health treatments and evidence-based psychedelic-assisted therapies, has announced the resignation of Donna Wong as a director. Wong's resignation is effective from June 24, 2024. Payton Nyquvest, Founder, Chair, and CEO of Numinus, expressed gratitude for Wong's contributions to the company.

Numinus Wellness has announced the planned acquisition of MedBright AI, with an aim to integrate AI-driven solutions into mental health services across the U.S. The acquisition will result in the formation of 'Numinus Intelligence' and will leverage MedBright's AI technology to enhance clinical operations and capitalize on reimbursable offerings. The deal is expected to strengthen Numinus' balance sheet with over $5 million in cash and securities. Leaders from MedBright will join Numinus' management and board, contributing extensive experience in U.S. healthcare operations. The transaction involves issuing 1.86 Numinus shares for each MedBright share, culminating in Numinus shareholders holding approximately 39% of the combined entity. The merger aims to drive revenue growth and profitability by expanding AI-enabled mental health services.

On June 7, 2024, Numinus Wellness clarified disclosures from two previous press releases dated May 30, 2024. The first release discussed Numinus' participation in Cybin's Phase 3 trials for major depressive disorder, led by Cedar Clinical Research in Murray, Utah. However, Numinus clarified it has no ownership in CYB003, and results will be shared by Cybin at their discretion. The second release covered Numinus' plans for a new community pilot and Numinus Network, targeting therapists and practitioners. Numinus emphasized that this initiative does not offer access to medical infrastructure for psychedelic therapies and that the subscription model's rollout is uncertain. Both releases included forward-looking statements subject to risks and uncertainties.